All articles by Staff Writer

• Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?

  NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders. According to…

• Risk adjusted net present value: What is the current valuation of Pfizer’s Ibuzatrelvir?

  Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19). According…

• Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-6234?

  AZD-6234 is a synthetic peptide commercialized by AstraZeneca, with a leading Phase I program in Obesity. According to Globaldata, it…

• Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s RYZ-101?

  RYZ-101 is a synthetic peptide commercialized by Bristol-Myers Squibb, with a leading Phase III program in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).…

• Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sipavibart?

  Sipavibart is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Coronavirus Disease 2019 (COVID-19). According…